Project Grant R21AG089134
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$455K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $2,969,644 to develop a novel positron emission tomography (PET) imaging probe targeting myeloperoxidase (MPO) activity for detecting neuroinflammation in neurodegenerative diseases. The Massachusetts General Hospital will design and screen potential PET agents for detecting MPO activity in the brain, characterize and validate candidate MPO PET...
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is funding the development and validation of "smart" chemiluminescence probes to enable high-throughput imaging for preclinical Alzheimer's disease (AD) research. The $2,389,865 award is being provided to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to advance a novel chemiluminescence probe called ADLUMIN-1 that has...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $7,179,562 to Sloan-Kettering Institute For Cancer Research from June 15, 2022 to May 31, 2025. The funding supports the discovery of novel positron emission tomography imaging probes to detect epichaperomes, which are emerging molecular targets in Alzheimer's disease and other cognitive disorders. Specifically, the grantee will work to identify...
This $812,030 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop and optimize noninvasive imaging biomarkers to track neuroinflammation in the early stages of Alzheimer's disease (AD). The research will utilize deuterium-based magnetic resonance techniques to investigate the relationship between astrocytic acetate metabolism and astrocyte reactivity, characterize spatiotemporal patterns of neuroinflammation and brain glucose hypometabolism...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a $332,096 pilot study evaluating the feasibility of non-invasive imaging techniques to monitor the metabolic and vascular functions of the brain and heart in a mouse model of Alzheimer's disease (AD). The study aims to investigate how moderate exercise may impact these key functions and potentially slow AD progression, while also examining any gender differences. The awardee, The...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $456,394 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to evaluate the feasibility of two novel scanning techniques for imaging mitochondrial function and availability in Alzheimer's disease (AD) models. The goal is to 1) image the availability of mitochondrial complex-I using the [18F]BCPP-EF PET tracer, and 2) assess the metabolic activity...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,310,950.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel diffusion MRI technology that will enable high-resolution, high-fidelity, and high-SNR imaging of the medial temporal lobe in Alzheimer's disease. The goal is to detect early microstructural changes in the perforant pathway and medial temporal lobe cortices, which could serve...
This federal Project Grant award in the amount of $374,000.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development and evaluation of a hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy targeting amyloid-beta aggregates for the treatment of Alzheimer's disease. The project aims to optimize the CAR-macrophage therapy for in vitro efficacy against amyloid-beta aggregates and inflammation reduction, as well as investigate its...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, for in vivo imaging of the GPR39 receptor in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The research aims to establish the efficacy of [11C]TM-N1324 PET imaging to quantify GPR39 levels, which are implicated in the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $837,500 to Yale University to characterize the properties and performance of the PET radiotracer [18F]3F4AP for detecting and quantifying demyelination and cerebral perfusion in Alzheimer's disease, mild cognitive impairment, and cognitively normal individuals. The project will conduct the first full pharmacokinetic evaluation of this tracer in human subjects, validate simplified imaging...